[
  {
    "ts": null,
    "headline": "Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains",
    "summary": "If you've been thinking about what to do with your Incyte shares, or whether now is a smart time to jump in, you’re not alone. The stock has been on the move lately, catching the attention of both careful investors and opportunists alike. In the past week alone, Incyte has climbed 3.4%, adding to a year-to-date rise of 25.9%. Over the last year, shareholders have enjoyed a 34.2% return, a marked turnaround from its rather sluggish five-year performance, which is still down 3.2%. That kind of...",
    "url": "https://finnhub.io/api/news?id=96575a8ebd25591fbdedccf2f19d150b000c25afe883d59003ef66e254c209bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760994362,
      "headline": "Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains",
      "id": 137174967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "If you've been thinking about what to do with your Incyte shares, or whether now is a smart time to jump in, you’re not alone. The stock has been on the move lately, catching the attention of both careful investors and opportunists alike. In the past week alone, Incyte has climbed 3.4%, adding to a year-to-date rise of 25.9%. Over the last year, shareholders have enjoyed a 34.2% return, a marked turnaround from its rather sluggish five-year performance, which is still down 3.2%. That kind of...",
      "url": "https://finnhub.io/api/news?id=96575a8ebd25591fbdedccf2f19d150b000c25afe883d59003ef66e254c209bf"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript",
    "summary": "Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript",
    "url": "https://finnhub.io/api/news?id=b3a06f41cb7e7c92f3e949f2b9678f374edae4fba2805acac494fc922169272b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760981071,
      "headline": "Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript",
      "id": 137170330,
      "image": "",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b3a06f41cb7e7c92f3e949f2b9678f374edae4fba2805acac494fc922169272b"
    }
  },
  {
    "ts": null,
    "headline": "Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice",
    "summary": "Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
    "url": "https://finnhub.io/api/news?id=33769946c5f684f0cfbd2186e79232498de6a4e068f0b5c00d752a472607a302",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760976003,
      "headline": "Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice",
      "id": 137174968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
      "url": "https://finnhub.io/api/news?id=33769946c5f684f0cfbd2186e79232498de6a4e068f0b5c00d752a472607a302"
    }
  }
]